Fromovich-Amit Y, Zivelin A, Rosenberg N, Tamary H, Landau M, Seligsohn U
Amalia Biron Research Institute of Thrombosis and Haemostasis, Chaim Sheba Medical Center, Tel Hashomer, Israel.
J Thromb Haemost. 2004 Oct;2(10):1774-81. doi: 10.1111/j.1538-7836.2004.00921.x.
Inherited factor (F)VII deficiency is rare in most populations but relatively common in Israel. The aim of this study was to characterize the molecular and functional defect in unrelated Israeli patients with FVII deficiency. Mutations were identified by direct sequencing of PCR-amplified genomic DNA fragments. Selected mutations were expressed in baby hamster kidney (BHK) cells and tested for binding to tissue factor (TF), activation by FXa and activation of FX. In 61 patients with FVII deficiency, the causative mutation in the FVII gene was discerned. The predominant mutation found in this and a previously reported cohort of 27 unrelated patients in Israel was Ala244Val substitution; of 121 independent mutant alleles defined in all 88 patients ascertained in Israel, 102 (84%) bore this alteration. Eleven additional mutations were identified of which one, Cys22Arg, is novel. Expression of the mutations in BHK cells revealed that four (Ala244Val, 11128delC, Leu300Pro and Cys22Arg) were cross-reacting material (CRM)- negative, and three (Ala294Val, Cys310Phe and Phe24del) were CRM-positive. As predicted by modeling, we observed no binding to TF of FVII Phe24del, diminished binding of FVII Cys310Phe and normal binding of FVII Ala294Val. The main defect of FVII Ala294Val was its inability to activate FX in the presence of TF. Coexpression of Ala294Val and Arg353Gln, a polymorphism known to affect FVII secretion, did not reveal an additive effect on FVII secretion, while coexpression of Ala244Val and Arg353Gln did yield an additive effect.
遗传性因子(F)VII缺乏症在大多数人群中较为罕见,但在以色列相对常见。本研究的目的是明确以色列非亲属FVII缺乏症患者的分子和功能缺陷。通过对聚合酶链反应(PCR)扩增的基因组DNA片段进行直接测序来鉴定突变。选择的突变在幼仓鼠肾(BHK)细胞中表达,并检测其与组织因子(TF)的结合、被FXa激活以及激活FX的能力。在61例FVII缺乏症患者中,发现了FVII基因的致病突变。在本研究以及之前报道的27例以色列非亲属患者队列中发现的主要突变是Ala244Val替代;在以色列确诊的所有88例患者中定义的121个独立突变等位基因中,102个(84%)存在这种改变。还鉴定出另外11种突变,其中一种Cys22Arg是新发现的。在BHK细胞中表达这些突变表明,四种(Ala244Val、11128delC、Leu300Pro和Cys22Arg)是交叉反应物质(CRM)阴性,三种(Ala294Val、Cys310Phe和Phe–24del)是CRM阳性。如通过建模所预测的,我们观察到FVII Phe–24del不与TF结合,FVII Cys310Phe的结合减少,而FVII Ala294Val的结合正常。FVII Ala294Val的主要缺陷是在存在TF的情况下无法激活FX。Ala294Val与已知影响FVII分泌的多态性Arg353Gln共表达时,未显示对FVII分泌有累加效应,而Ala244Val与Arg353Gln共表达时确实产生了累加效应。